Type VI collagen turnover-related peptides-novel serological biomarkers of muscle mass and anabolic response to loading in young men

Journal of Cachexia, Sarcopenia and Muscle

Volumn 4, Issue 4, 2013, Pages 267-275

  Nedergaard, Anders ^a,b   Sun, Shu ^a,c   Karsdal, Morten A ^a   Henriksen, Kim ^a   Kjær, Michael ^b   Lou, Yunyun ^c   He, Yi ^c   Zheng, Qinlong ^c   Suetta, Charlotte ^b  

^a Nordic Bioscience Inc   (Denmark)

^b BISPEBJERG HOSPITAL   (Denmark)

^c Nordic Bioscience Beijing   (China)

Author keywords

Biomarker; Disuse; Immobilization; Remobilization; Resistance exercise; Skeletal muscle

Indexed keywords

BIOLOGICAL MARKER; COLLAGEN TYPE 6; TYPE VI COLLAGEN N TERMINAL GLOBULAR DOMAIN EPITOPE; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CIRCADIAN RHYTHM; CIRCULATION; COLLAGEN DEGRADATION; CONTROLLED STUDY; ENZYME LINKED IMMUNOSORBENT ASSAY; HUMAN; HUMAN TISSUE; IMMOBILIZATION; MALE; MUSCLE CONTRACTION; MUSCLE MASS; MUSCLE STRENGTH; NORMAL HUMAN; PHYSICAL ACTIVITY; PRIORITY JOURNAL; PROTEIN DEGRADATION; QUADRICEPS FEMORIS MUSCLE; RESISTANCE TRAINING; SEROLOGY;

EID: 84888024148     PISSN: 21905991     EISSN: 21906009     Source Type: Journal    
DOI: 10.1007/s13539-013-0114-x     Document Type: Article

References (34)

1. for the International Working Group on Sarcopenia, Cesari M, Fielding RA, Pahor M, Goodpaster B, Hellerstein M, et al. Biomarkers of sarcopenia in clinical trials-recommendations from the International Working Group on Sarcopenia. J Cachexia Sarcopenia Muscle. 2012;3: 181-90.
2. Pahor M, Manini T, Cesari M. Sarcopenia: clinical evaluation, biological markers and other evaluation tools. J Nutrition. 2009;13: 724-8.
3. FDA Administration: Challenge and opportunity on the critical path to new medical products, 2nd edn. U. S. Department of Health and Human Services, Food and Drug Administration 2004.
4. Karsdal MA, Henriksen K, Leeming DJ, Mitchell P, Duffin K, Barascuk N. Biochemical markers and the FDA critical path: how biomarkers may contribute to the understanding of pathophysiology and provide unique and necessary tools for drug development. Biomarkers. 2009;14: 181-202.
5. Zou Y, Zhang R-Z, Sabatelli P, Chu M-L, Bönnemann CG. Muscle interstitial fibroblasts are the main source of collagen VI synthesis in skeletal muscle: implications for congenital muscular dystrophy types Ullrich and Bethlem. J Neuropathol Exp Neurol. 2008;67: 144-54.
6. Reznick AZ, Menashe O, Bar-Shai M, Coleman R, Carmeli E. Expression of matrix metalloproteinases, inhibitor, and acid phosphatase in muscles of immobilized hindlimbs of rats. Muscle Nerve. 2003;27: 51-9.
7. Bönnemann CG. The collagen VI-related myopathies: muscle meets its matrix. Nat Rev Neurol. 2011;7: 379-90.
8. Liu X. Emerging ideas: matrix metalloproteinase-2 in muscle atrophy. Clin Orthop Relat Res. 2011;469: 1797-9.
9. Giannelli G, De Marzo A, Marinosci F, Antonaci S. Matrix metalloproteinase imbalance in muscle disuse atrophy. Histol Histopathol. 2005;20: 99-106.
10. Veidal SS, Karsdal MA, Vassiliadis E, Nawrocki A, Larsen MR, Nguyen QHT, et al. MMP mediated degradation of type VI collagen is highly associated with liver fibrosis-identification and validation of a novel biochemical marker assay. PLoS One. 2011;6: e24753.
11. Suetta C, Hvid LG, Justesen L, Christensen U, Neergaard K, Simonsen L, et al. Effects of aging on human skeletal muscle after immobilization and retraining. J Appl Physiol. 2009;107: 1172-80.
12. Lemoine JK, Haus JM, Trappe SW, Trappe TA. Muscle proteins during 60-day bedrest in women: impact of exercise or nutrition. Muscle Nerve. 2009;39: 463-71.
13. Haus JM, Carrithers JA, Carroll CC, Tesch PA, Trappe TA. Contractile and connective tissue protein content of human skeletal muscle: effects of 35 and 90 days of simulated microgravity and exercise countermeasures. Am J Physiol Regul Integr Comp Physiol. 2007;293: R1722-7.
14. Saltin B, Grimby G. Physiological analysis of middle-aged and old former athletes. Comparison with still active athletes of the same ages. Circulation. 1968;38: 1104-15.
15. Hvid L, Aagaard P, Justesen L, Bayer ML, Andersen JL, Ortenblad N, et al. Effects of aging on muscle mechanical function and muscle fiber morphology during short-term immobilization and subsequent retraining. J Appl Physiol. 2010;109: 1628-34.
16. Miller BF, Olesen JL, Hansen M, Dossing S, Crameri RM, Welling RJ, et al. Coordinated collagen and muscle protein synthesis in human patella tendon and quadriceps muscle after exercise. J Physiol. 2005;567: 1021-33.
17. Bleeker MWP, Hopman MTE, Rongen GA, Smits P. Unilateral lower limb suspension can cause deep venous thrombosis. Am J Physiol Regul Integr Comp Physiol. 2004;286: R1176-7.
18. Sochart DH, Hardinge K. The relationship of foot and ankle movements to venous return in the lower limb. J Bone Joint Surg Br. 1999;81: 700-4.
19. Bay-Jensen AC, Leeming DJ, Kleyer A, Veidal SS, Schett G, Karsdal MA. Ankylosing spondylitis is characterized by an increased turnover of several different metalloproteinase-derived collagen species: a cross-sectional study. Rheumatol Int. 2011;32: 3565-72.
20. Bay-Jensen A-C, Sondergaard BC, Christiansen C, Karsdal MA, Madsen SH, Qvist P. Biochemical markers of joint tissue turnover. ASSAY and Drug Development Technologies. 2010;8: 118-24.
21. Bürger MZ. Beiträge zum Kreatininstoffwechsel: I. Die Bedeutung des KreatininKoefizienten für die quantitative Bewertung der Muskulatur als Körpergewichtskomponente. II. die Störungen des Muskelstoffwechsels. Zeitschrift fd ges Exper Med. 1919;9: 361-99.
22. Wang ZM, Gallagher D, Nelson ME, Matthews DE, Heymsfield SB. Total-body skeletal muscle mass: evaluation of 24-h urinary creatinine excretion by computerized axial tomography. Am J Clin Nutr. 1996;63: 863-9.
23. Heymsfield SB, Arteaga C, McManus C, Smith J, Moffitt S. Measurement of muscle mass in humans: validity of the 24-hour urinary creatinine method. Am J Clin Nutr. 1983;37: 478-94.
24. Heymsfield S, McManus C, Smith J. Anthropometric measurement of muscle mass: revised equations for calculating bone-free arm muscle area. Am J Clin Nutr. 1982;36: 680-90.
25. Wang Z, Deurenberg P, Matthews DE, Heymsfield SB. Urinary 3-methylhistidine excretion: association with total body skeletal muscle mass by computerized axial tomography. JPEN J Parenter Enteral Nutr. 1998;22: 82-6.
26. Calles-Escandon J, Cunningham JJ, Snyder P, Jacob R, Huszar G, Loke J, et al. Influence of exercise on urea, creatinine, and 3-methylhistidine excretion in normal human subjects. Am J Physiol. 1984;246: E334-8.
27. Chinkes DL. Methods for measuring tissue protein breakdown rate in vivo. Curr Opin Clin Nutr Metab Care. 2005;8: 534-7.
28. Rennie MJ, Phillips S, Smith K. Reliability of results and interpretation of measures of 3-methylhistidine in muscle interstitium as marker of muscle proteolysis. J Appl Physiol. 2008;105: 1380-1. author reply 1382-1383.
29. Stickel F, Urbaschek R, Schuppan D, Poeschl G, Oesterling C, Conradt C, et al. Serum collagen type VI and XIV and hyaluronic acid as early indicators for altered connective tissue turnover in alcoholic liver disease. Dig Dis Sci. 2001;46: 2025-32.
30. Tandon P, Ney M, Irwin I, Ma MM, Gramlich L, Bain VG, et al. Severe muscle depletion in patients on the liver transplant wait list-its prevalence and independent prognostic value. Liver Transpl. 2012;18: 1209-16.
31. Lin S-Y, Chen W-Y, Lee F-Y, Huang C-J, Sheu WH-H. Activation of ubiquitin-proteasome pathway is involved in skeletal muscle wasting in a rat model with biliary cirrhosis: potential role of TNF-alpha. Am J Physiol Endocrinol Metab. 2005;288: E493-501.
32. Matsuzaki Y, Miyazaki T, Ohkoshi N, Miyakawa S, Bouscarel B, Tanaka N. Degeneration of skeletal muscle fibers in the rat administrated carbon tetrachloride: similar histological findings of the muscle in a 64-year-old patient of LC with muscle cramp. Hepatol Res. 2002;24: 368-78.
33. Weber FL, Macechko PT, Kelson SR, Karajiannis E, Hassan MO. Increased muscle protein catabolism caused by carbon tetrachloride hepatic injury in rats. Gastroenterology. 1992;102: 1700-6.
34. Iki M, Akiba T, Matsumoto T, Nishino H, Kagamimori S, Kagawa Y, et al. JPOS Study Group: reference database of biochemical markers of bone turnover for the Japanese female population. Japanese Population-based Osteoporosis (JPOS) Study. Osteoporos Int. 2004;15: 981-91.